-The Business Standard The proposed Pharma pricing policy may give room to drug makers to escape price control. While the policy is primarily aimed at making essential medicines affordable, many feel the spirit is missing in the recommendations put forward by a group of ministers a few days ago. For instance, the ministerial panel has proposed to regulate prices of only 348 essential medicines and keep combination products out of control —...

-The Hindu “Environmental impact assessment tends to ignore wider impact on biodiversity” In a move that will bring cheer to wildlife lovers but could dismay industry lobbyists already complaining about the difficulty in obtaining green clearances, the government plans to add biodiversity conservation as a new criterion to grant environmental and forest clearances. “There is no biodiversity clearance till now,” admitted Union Environment Minister Jayanthi Natarajan, speaking ahead of the United Nations summit...

-The Times of India India will, for the first time, put a cap on the maximum price at which essential drugs, like some commonly used anti-AIDS and anti-cancer drugs, besides a horde of painkillers, anti-TB drugs, sedatives, lipid lowering agents and steroids, can be sold in the country. In a landmark decision, a group of ministers (GoM) headed by agriculture minister Sharad Pawar on Thursday cleared the proposal to bring all 348...

-The Times of India MUMBAI: Consumers can look forward to a reduction in prices of essential medicines, with the Sharad Pawar-led Group of Ministers (GoM) planning to take a final decision on the pharmaceutical policy soon. The GoM will meet on September 27 to examine options under the market price-based mechanism to cap prices of drugs, which may lead to a reduction ranging from 25% to even 90% in some cases,...

-The Economic Times MUMBAI: In a victory to generic drugmakers, the Intellectual Property Appellate Board (IPAB) of Chennai has dismissed German Pharma major Bayer's plea, seeking a stay on the Compulsory Licence issued to Hyderabad-based drugmaker Natco. The Compulsory Licence (CL) issued by the Controller of Patents in March this year allowed Natco to make and sell a generic version of Nexavar - used for treating liver and kidney cancer - at...